<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00919958</url>
  </required_header>
  <id_info>
    <org_study_id>PLX-PAD 1202-1</org_study_id>
    <nct_id>NCT00919958</nct_id>
  </id_info>
  <brief_title>Safety of Intramuscular Injection of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia</brief_title>
  <official_title>Phase I Study of Intramuscular (IM) Injection of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia. PLX-PAD Are Mesenchymal-like Stromal Cells Derived From a Full Term Placenta. These Placental Adherent Stromal Cells (ASCs) Are Expanded in the Company's Proprietary PluriXTM 3D Bioreactor System. PLX Cells Are Immune Privileged and Possess Immunomodulatory Properties.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pluristem Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pluristem Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The The purpose of this study is to determine the safety of PLX-PAD single dose,
      Intra-muscular injection for the treatment of CLI patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PLX-PAD are mesenchymal-like stromal cells derived from a full term placenta, termed PLX-PAD,
      and intended for the treatment of Critical Limb Ischemia
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events, Safety laboratory values and ECG findings</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunological reaction</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumorigenesis</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <condition>Peripheral Vascular Disease</condition>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>PLX-PAD low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PLX-PAD intermediate dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PLX-PAD high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PLX-PAD IM injection</intervention_name>
    <description>Single treatment; multiple injections</description>
    <arm_group_label>PLX-PAD low dose</arm_group_label>
    <arm_group_label>PLX-PAD intermediate dose</arm_group_label>
    <arm_group_label>PLX-PAD high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of critical limb ischemia defined as persistent, recurring ischemic rest
             pain for at least two (2) weeks, and/or ulceration or gangrene of the foot or toe,
             with ABI &lt; 0.4 or/and TBI &lt; 0.4 or transcutaneous partial pressure of oxygen ≤ 30 mmHg
             pO2 at the foot.

          2. Rutherford category 4-5

          3. No acceptable options for re-vascularisation as confirmed by angiographic imaging
             results or by color flow duplex ultrasound obtained within 6 months prior screening
             visit and signed approval of vascular surgeon.

          4. In the opinion of the investigator, major amputation is not anticipated over a period
             of three (3) months.

        Exclusion Criteria:

          1. Uncontrolled hypertension (defined as diastolic blood pressure &gt; 110 mmHg or systolic
             blood pressure &gt; 180 mmHg during screening).

          2. Poorly controlled diabetes mellitus (HbA1c &gt; 9%)

          3. Wounds with severity greater than Grade 2 on the Wagner Scale

          4. Life-threatening ventricular arrhythmia - except if an ICD is implanted - or unstable
             angina pectoris - characterized by increasingly frequent episodes with modest exertion
             or at rest, worsening severity, and prolonged

          5. ST segment elevation myocardial infarction and/or TIA/CVA within six (6) months prior
             to enrollment. Patients with severe congestive heart failure (i.e. NYHA Stage IV)

          6. In the opinion of the investigator, the patient is unsuitable for cellular therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>81 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Carsten Tschöpe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Franziskus-Krankenhaus</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2009</study_first_submitted>
  <study_first_submitted_qc>June 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2009</study_first_posted>
  <last_update_submitted>June 17, 2012</last_update_submitted>
  <last_update_submitted_qc>June 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral Artery Disease</keyword>
  <keyword>Peripheral Vascular Disease</keyword>
  <keyword>Critical limb ischemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

